FDA Expands Approval for Antidepressant Nasal Spray
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression.
Parkside Psychiatric Hospital has a Spravato outpatient clinic on-site and has seen more than 20 patients each week with positive results.
It was initially approved in 2019 to treat resistant depression.
FDA Approval
Spravato is a nasal... Read More.
